Contact Us
Drug Search Results
More Filters [+]

Trifarotene

Alternative Names: trifarotene, CD5789, CD 5789, CD-5789, aklief
Latest Update: 2024-12-13
Latest Update Note: Clinical Trial Update

Product Description

Trifarotene is the latest new retinoid approved for the treatment of acne by the FDA in over 20 years. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996910/)

Mechanisms of Action: RAR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Belgium | Bulgaria | Canada | Chile | Croatia | Czech | Denmark | Ecuador | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | Norway | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Spain | Sweden | Switzerland | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: Acne Vulgaris

Known Adverse Events: Sunburn | Pruritus

Company: Galderma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trifarotene

Countries in Clinic: United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Acne Vulgaris

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TRFC-2405

P1

Completed

Acne Vulgaris

2024-06-20

TRFC-2208

P1

Completed

Acne Vulgaris

2023-07-13

21%
TRIF-2101

P3

Completed

Acne Vulgaris

2023-05-09

Recent News Events

Date

Type

Title

10/25/2024

News Article

 Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology Conference

07/25/2024

News Article

 Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

04/24/2024

News Article

 Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

02/29/2024

News Article

 Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions